Bank of New York Mellon’s Century Therapeutics IPSC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$733K Buy
299,014
+286,117
+2,218% +$654K ﹤0.01% 3544
2026
Q1
$29.1K Buy
+12,897
New +$27.1K ﹤0.01% 4163
2025
Q2
Sell
-105,529
Closed -$50.2K 4204
2025
Q1
$50.2K Hold
105,529
﹤0.01% 4054
2024
Q4
$107K Sell
105,529
-465
-0.4% -$633 ﹤0.01% 4027
2024
Q3
$181K Sell
105,994
-43,006
-29% -$84.3K ﹤0.01% 3938
2024
Q2
$380K Buy
149,000
+78,088
+110% +$247K ﹤0.01% 3711
2024
Q1
$296K Sell
70,912
-19,644
-22% -$83.1K ﹤0.01% 3781
2023
Q4
$301K Buy
90,556
+13,950
+18% +$25.4K ﹤0.01% 3800
2023
Q3
$153K Sell
76,606
-408
-0.5% -$1.09K ﹤0.01% 4027
2023
Q2
$243K Buy
77,014
+17,041
+28% +$54.9K ﹤0.01% 3920
2023
Q1
$208K Sell
59,973
-283
-0.5% -$1.24K ﹤0.01% 3903
2022
Q4
$309K Buy
60,256
+2,299
+4% +$21.7K ﹤0.01% 3780
2022
Q3
$573K Buy
57,957
+10,608
+22% +$112K ﹤0.01% 3504
2022
Q2
$398K Buy
47,349
+3,468
+8% +$34K ﹤0.01% 3729
2022
Q1
$552K Buy
43,881
+10,524
+32% +$139K ﹤0.01% 3647
2021
Q4
$529K Buy
33,357
+4,425
+15% +$83.1K ﹤0.01% 3780
2021
Q3
$727K Buy
+28,932
New +$783K ﹤0.01% 3586

Other funds holding IPSC

Bank of New York Mellon's IPSC Position: Q2 2026 in Review

Bank of New York Mellon increased its Century Therapeutics (IPSC) stake by 2,218% in Q2 2026, buying an estimated $654K and bringing the position to 299,014 shares worth $733K. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Bank of New York Mellon first reported a position in IPSC in Q3 2021 and has held it in 17 quarters since. 28 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Bank of New York Mellon held 299,014 shares of Century Therapeutics worth $733K as of Q2 2026.
  • Bank of New York Mellon bought 286,117 Century Therapeutics shares in Q2 2026, an estimated $654K.
  • Century Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3544 holding.
  • Bank of New York Mellon first reported a position in Century Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • 28 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.